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Abstract
Major histocompatibility complex (MHC) class II antigens are expressed on human foreskin keratinocytes (HFKs) following exposure
to interferon gamma. The expression of MHC class II proteins on the cell surface may allow keratinocytes to function as antigen-presenting
cells and induce a subsequent immune response to virus infection. Invariant chain (Ii) is a chaperone protein which plays an important role
in the maturation of MHC class II molecules. The sequential degradation of Ii within acidic endocytic compartments is a key process
required for the successful loading of antigenic peptide onto MHC class II molecules. Since human papillomavirus (HPV) 16 E5 can inhibit
the acidification of late endosomes in HFKs, the E5 protein may be able to affect proper peptide loading onto the MHC class II molecule.
To test this hypothesis, HFKs were infected with either control virus or a recombinant virus expressing HPV16 E5 and the infected cells
were subsequently treated with interferon-. ELISAs revealed a decrease of MHC class II expression on the surface of E5-expressing cells
compared with control virus-infected cells after interferon treatment. Western blot analysis showed that, in cells treated with interferon
gamma, E5 could prevent the breakdown of Ii and block the formation of peptide-loaded, SDS-stable mature MHC class II dimers,
correlating with diminished surface MHC class II expression. These data suggest that HPV16 E5 may be able to decrease immune
recognition of infected keratinocytes via disruption of MHC class II protein function.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
The human papillomavirus (HPV) 16 E5 gene encodes
an 83 amino acid hydrophobic protein that has been found
localizing to the cell membrane, endoplasmic reticulum
(ER), Golgi apparatus, and endosomal compartment (Con-
rad et al., 1993). HPV16 E5 has been reported to associate
with EGF receptors (EGFR) (Hwang et al., 1995) and en-
hance EGFR-mediated biological activity in the presence of
EGF (Pim et al., 1992; Leechanachai et al., 1992; Crusius et
al., 1998; Zhang et al., 2002). E5 also binds the 16-kDa
subunit (subunit C) of vacuolar-proton-ATPase (Conrad et
al., 1993) and decreases acidification of endocytic compart-
ments (Straight et al., 1995).
The major histocompatibility complex (MHC) class II
molecule is a heterodimeric protein composed of an  and
 subunit, whose main function is to deliver antigenic pep-
tides from endocytic compartments to the cell surface for
recognition by CD4 T cells (Wolf and Ploegh, 1995;
Benaroch et al., 1995). MHC class II antigens are synthe-
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sized in the ER (Cresswell et al., 1987; Cresswell, 1994),
where the  and  subunits associate with a chaperone
protein called the invariant chain (Ii). The Ii trimer is
sorted in the endocytic compartments with the Ii being
sequentially degraded to leupeptin-induced peptide (LIP)
migrating at 21–22 kDa, small leupeptin-induced peptide
(SLIP) migrating at 12–14 kDa, and class II-associated Ii
peptide (CLIP) by existing cysteine and noncysteine pro-
teases (Peters et al., 1991; Amigorena et al., 1994; West et
al., 1994; Benaroch et al., 1995). The CLIP finally is ex-
changed with an antigenic peptide, a process which is cat-
alyzed by HLA-DM (Neefjes and Ploegh, 1992; Loss and
Sant, 1993; Benaroch et al., 1995; Chapman, 1998). The
antigenic peptide-loaded  dimer is then expressed on the
cell surface as a mature MHC class II molecule.
Human keratinocytes, the host cells of HPV, normally do
not express MHC class II molecules. However, it has been
well documented that keratinocytes can express MHC class
II (HLA-DR, -DP, and -DQ) in many skin disorders with
associated T lymphocyte infiltrates (Nickoloff et al., 1985;
Aubock et al., 1986; Gawkrodger et al., 1987; Mutlu et al.,
1991; Glew et al., 1992; Coleman and Stanley, 1994; Mota
et al., 1999). Human foreskin keratinocytes also show im-
munological activity (expressing HLA-DR, HLA-DM, and
Ii) when stimulated by interferon- (Albanesi et al., 1998).
The expression of MHC class II molecules may allow ker-
atinocytes to function as antigen-presenting cells and induce
a subsequent immune response (Nickoloff et al., 1985;
Aubock et al., 1986; Gawkrodger et al., 1987; Mutlu et al.,
1991; Glew et al., 1992; Coleman and Stanley, 1994; Mota
et al., 1999).
Concanamycin B, which is an inhibitor of the vacuolar-
proton-ATPase, can block the acidification of late endo-
somes. Treatment of cells with this inhibitor prevents the
activation of the proteases required for the final stages of Ii
proteolysis. The result is the accumulation of Ii degradation
intermediates LIP and SLIP which remain bound to class II
 and  subunits within the endosomal compartments
(Benaroch et al., 1995). Release of these Ii fragments is
necessary for the functional maturation of MHC class II
proteins (Neefjes and Ploegh, 1992; Loss and Sant, 1993;
Benaroch et al., 1995). Thus, only after complete proteoly-
sis and dissociation of Ii fragments can MHC class II 
bind antigenic peptides and form stable complexes as de-
tectable on sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE) (Neefjes and Ploegh, 1992;
Benaroch et al., 1995). These observations led us to inves-
tigate whether HPV16 E5, which binds the subunit C of
vacuolar-proton-ATPase and abrogates its ability to main-
tain a very low pH in endocytic compartments, might play
a similar role to concanamycin B in affecting the maturation
of MHC class II in human foreskin keratinocytes. This
property of HPV16 E5 would therefore allow infected cells
to escape recognition by host immune surveillance.
Here, assays were carried out to examine MHC class II and
Ii in human foreskin keratinocytes infected with a control
retroviral vector, LXSN, or a recombinant retrovirus express-
ing HPV16 E5 after interferon- treatment. ELISA results
indicate a decrease in MHC class II expression on the surface
of E5-expressing cells compared with control virus-infected
cells after interferon treatment. Western blot analysis also dem-
onstrated E5 could inhibit the complete degradation of Ii and
block the formation of peptide-loaded, SDS-stable MHC class
II expression on the surface of keratinocytes.
Results
MHC class II protein expression is down-regulated on the
surface of E5-expressing cells
Primary HFKs were isolated from neonatal foreskin from
seven different individuals and infected with either the
LXSN or L(16E5)SN retrovirus. E5 expression was verified
by Northern blot analysis as previously described (Zhang et
al., 2002). To determine whether E5 can affect the surface
expression of MHC class II molecules, LXSN- and
L(16E5)SN-infected cells were starved for EGF and treated
with 100 U/ml interferon- for 24 h followed by culture in
K-SFM containing 100 ng/ml of EGF and 500 U/ml of
interferon- for 5 and 24 h. Parallel cells, maintained in
complete K-SFM, served as untreated controls. Following
induction of MHC class II gene expression with interfer-
on-, cells were fixed with 1% paraformaldehyde and an
ELISA was carried out using the L243 antibody which
recognizes the MHC class II  dimer. The HFKs from all
seven individuals showed induction of MHC class II surface
expression after interferon treatment (Fig. 1 and data not
shown). The cells isolated from five individuals (F551,
F554, F556, F560, F561) showed decreases in MHC class II
surface expression in E5-expressing cells of 22–45% after
5 h of EGF stimulation and 19–39% reduction after 24 h
(Fig. 1, Table 1). Cells from only two individuals (F558,
F562) showed a lack of significant change, with a 2–6%
decrease in MHC class II cell-surface expression at either
time point (Table 1). Due to the heterogeneity in human
MHC class II alleles at the structural gene level, the ob-
served differences in the effect of E5 on MHC class II
expression were not unexpected. The ability of HPV16 E5
to disrupt the surface expression of MHC class II molecules
on cells from the majority of individuals tested did, how-
ever, suggest this viral protein might perturb the function of
MHC class II proteins.
HPV16 E5 prevents the degradation of invariant chain
The sequential proteolytic degradation of Ii chain from
its C-terminus is a pH-dependent process (Blum and Cress-
well, 1988; Neefjes and Ploegh, 1992; Benaroch et al.,
1995; Chapman, 1998). HPV16 E5 has been shown to
inhibit the acidification of endosomes in human keratino-
cytes (Straight et al., 1995). To analyze whether E5 affected
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the processing of the Ii, LXSN- and L(16E5)SN-infected
HFKs from F551 were starved for EGF in the presence of
100 U/ml of interferon-. After 24 h the cells were stimu-
lated with 100 ng/ml of EGF and 500 U/ml of interferon-
for 2, 5, and 24 h. The cells were lysed and cell lysates were
boiled in 2 SDS sample buffer without -mercaptoethanol
and analyzed by Western blot using monoclonal antibody
PIN1.1, which recognizes the N-terminus of Ii chain.
PIN1.1 can detect both the intact Ii and the intermediate
products (LIP), which accumulate when the terminal stages
of degradation are blocked. As a positive control, leupeptin,
which blocks the activity of endosomal cysteine proteases
required for Ii processing, was added at 0.5 mM (Riese et
al., 1996) to a sample of the LXSN-infected cells. Two
forms of intact Ii, Ii33 and Ii41, which result from alternate
exon splicing, were expressed in both E5-expressing and
control cells after interferon- treatment (Fig. 2). LIP was
detected in E5-expressing cells and leupeptin-treated cells
but not control cells. Similar results were seen with E5-
expressing HFKs from F560 and F561, but not from F558
(data not shown). These results suggest that the terminal
stages of Ii degradation were inhibited in E5-expressing
cells exhibiting decreased MHC class II surface expression
(Table 1). Association of class II molecules with LIP is
known to cause the intracellular retention of these com-
plexes in endosomes because LIP, similar to the intact Ii,
bears an endosome retention signal in its cytoplasmic tail.
Therefore, complete proteolysis and release of Ii fragment
from MHC class II is necessary for class II protein transit to
the cell surface. Thus, the observed inhibition of MHC class
II protein surface expression is due to the negative effect of
E5 on Ii proteolysis.
HPV16 E5 blocks the formation of mature SDS-stable
class II  dimers
Peptide-loaded MHC class II  dimers are resistant
to dissociation upon SDS treatment (Billing et al., 1976;
Cresswell, 1977; Wettstein et al., 1991; Sadegh-Nasseri and
Germain, 1991) and migrate as a dimer under these condi-
tions on SDS–PAGE. When Ii or its fragments are associ-
ated with class II complexes, the - and -subunit associ-
ation is destabilized upon exposure to SDS. Even peptide-
loaded or mature MHC class II dimers dissociate when
boiled prior to SDS–PAGE (Koch and Hammerling, 1982).
Human keratinocytes acquire all the features of antigen-
presenting cells when they are treated with interferon-
(Albanesi et al., 1998), including the formation of peptide-
loaded, SDS-stable MHC class II dimers. To assess whether
HPV16 E5 could affect the maturation of MHC class II,
LXSN- and L(16E5)SN-infected HFKs from F551 were
treated with interferon- as described above. The cells were
Fig. 1. MHC class II was down-regulated on the surface of E5-expressing cells. (A) LXSN- and L(16E5)SN-infected HFKs from one individual (F551) were
starved for EGF, treated with 100 U/ml interferon- for 24 h, and then changed to K-SFM containing 100 ng/ml EGF and 500 U/ml interferon- for 5 or
24 h. Parallel cells were kept in complete K-SFM as untreated control cells. All cells were fixed with 1% paraformaldehyde and ELISA was done using the
L243 antibody which recognizes the MHC class II dimer. Results were corrected for nonspecific antibody binding to cells via analysis of identical samples
using irrelevant control antibody NN4. The values shown are the average  standard deviation of triplicate cultures.
Table 1
HFKs from seven different individuals were analyzed by ELISA to
determine the effect of HPV16 E5 on MHC class II cell-surface expression
5 h OD405a 24 h OD405a
Individual LXSN 16 E5 Decrease
(%)
LXSN 16 E5 Decrease
(%)
F551 0.178 0.098 45 0.401 0.266 34
F554 0.141 0.087 38 0.315 0.230 27
F556 0.271 0.191 30 0.709 0.529 25
F560 0.165 0.128 22 0.505 0.308 39
F561 0.270 0.152 44 0.404 0.329 19
F558 0.248 0.235 5 0.358 0.336 6
F562 0.133 0.131 2 0.268 0.263 2
a Results are the average of triplicate samples with standard devia-
tion 20%.
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lysed at 5 and 24 h after EGF stimulation, and cell lysates
were incubated with an equal volume of 2 SDS sample
buffer without -mercaptoethanol for 2 h at room temper-
ature and not boiled prior to electrophoresis to facilitate
detection of mature peptide-loaded MHC class II molecules.
Samples from the same cell lysates were also boiled in an
equal volume of 2 SDS sample buffer containing -mer-
captoethanol, conditions which result in the dissociation of
MHC class II  and  dimers irrespective of whether Ii or
peptides are bound. The treated lysates were analyzed by
Western blot with monoclonal antibodies DA6.147 and
XD5.A11 recognizing the  and  subunits of the MHC
class II dimer, respectively. Densitometric analysis of the
autoradiograms (Fig. 3) showed that under nonreduced,
nonboiled conditions the amount of SDS-stable MHC class
II dimers decreased by 24 and 40% at 5 and 24 h, respec-
tively, in E5-expressing cells relative to control LXSN-
infected cells. The levels of SDS-stable MHC class II
dimers in cells decreased by 63% at 24 h in leupeptin-
treated cells. A corresponding increase in the amount of
dissociated  and  subunits was noted in cells expressing
E5 (Fig. 3). Under reduced and boiled conditions on SDS–
PAGE, all class II dimers were dissociated to  and 
subunits with similar levels of the free subunits found in
both cell populations (Fig. 3). These results suggest that the
formation of peptide-loaded mature SDS-stable, MHC class
II molecules in E5-expressing cells was inhibited. Similar
results were seen with E5-expressing HFKs from F560 and
F561, where MHC class II surface expression is decreased,
but not with F558 HFKs where MHC class II expression is
not decreased (data not shown).
Discussion
MHC class II proteins exist as surface-expressed het-
erodimers that deliver antigenic peptides from endocytic
compartments to the cell surface for recognition by CD4 T
cells (Wolf and Ploegh, 1995; Benaroch et al., 1995). The
MHC class II molecules, composed of an  and  subunit,
are synthesized in the ER (Cresswell et al., 1987; Cresswell,
1994) and associate with the chaperone protein, invariant
chain (Ii), which directs the Ii trimer to the endocytic
pathway (Peters et al., 1991; Amigorena et al., 1994; West
et al., 1994; Benaroch et al., 1995). In late endosomal
compartments Ii is sequentially degraded from full length to
LIP and then to SLIP. In the terminal stages of Ii proteol-
ysis, the endosomal retention signal on LIP and SLIP are
cleaved with only a small peptide CLIP remaining in the
ligand-binding groove of MHC class II. Endogenous or
exogenous antigenic peptides are able to bind to MHC class
II complexes when CLIP is removed with the formation of
an SDS-resistant, -peptide complex. The SDS-stable
phenotype is a marker of MHC class II maturation and
typically associated with the acquisition of peptide ligands
within the MHC class II binding groove (Stebbins et al.,
1995). The endosomal proteolysis of Ii is a pH-dependent
process since a strong vacuolar proton-ATPase inhibitor
concanamycin B and lysosomotropic agent chloroquine can
inhibit the breakdown of Ii and block the maturation of
MHC class II molecules (Blum and Cresswell, 1988; Neefjes
and Ploegh, 1992; Benaroch et al., 1995; Chapman, 1998).
Human keratinocytes, the host of HPV, typically do not
express MHC class II proteins in contrast with professional
Fig. 2. HPV16 E5 prevents the degradation of invariant chain. LXSN- and L(16E5)SN-infected F551 HFKs were starved for EGF and treated with 100 U/ml
interferon- for 24 h and then stimulated with 100 ng/ml EGF and 500 U/ml interferon- for 2, 5, and 24 h prior to cell lysis. Leupeptin (0.5 mM) was added
during the interferon treatment to LXSN-infected cells to promote the accumulation of Ii fragments. The lysates were boiled in 2 SDS sample buffer without
-mercaptoethanol and analyzed by Western blot with monoclonal antibody PIN1.1. The results shown are representative of three independent infections of
F551.
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antigen-presenting cells such as dendritic cells, B cells, and
macrophages. Thus, in normal human epidermis, MHC
class II molecules are expressed only on Langerhans cells
(Mommaas et al., 1995). However, in many skin disorders,
human keratinocytes express detectable MHC class II
(HLA-DR, -DP, -DQ) accompanied by activated CD4 T
lymphocyte infiltration (Nickoloff et al., 1985; Aubock et
al., 1986; Gawkrodger et al., 1987; Mutlu et al., 1991; Glew
et al., 1992; Coleman and Stanley, 1994; Mota et al., 1999).
MHC class II molecules are also expressed in HPV-related
premalignant cervical epithelium and cervical carcinoma
(Glew et al., 1992; Coleman and Stanley, 1994; Mota et al.,
1999). Prior studies have shown that human foreskin kera-
tinocytes can produce peptide-loaded MHC class II mole-
cules as well as Ii33, Ii41, and HLA-DM after interferon-
stimulation (Albanesi et al., 1998). Thus, the expression of
MHC class II molecules on human keratinocytes during
certain dermatoses is likely mediated by interferon- pro-
duced by activated T lymphocytes (Nickoloff et al., 1985;
Aubock et al., 1986; Vardy et al., 1990; Coleman and
Stanley, 1994). Cytokine-mediated induction of MHC class
II proteins and accessory molecules such as Ii which facil-
itate antigen presentation may be critical for immunological
detection and clearance of HPV-infected and -transformed
cells (Glew et al., 1992; Coleman and Stanley, 1994; Mota
et al., 1999).
The HPV16 E5 is a small hydrophobic protein which
shows diverse biological activity (Pim et al., 1992; Leecha-
nachai et al., 1992; Hwang et al., 1995; Straight et al., 1995;
Oelze et al., 1995; Stoppler et al., 1996; Crusius et al., 1997,
1998; Thomsen et al., 1999, 2000; Zhang et al., 2002). A
key characteristic of HPV16 E5 is its ability to associate
with the epidermal growth factor receptor (Hwang et al.,
1995) and to stimulate this receptor’s transforming activity
(Pim et al., 1992; Leechanachai et al., 1992; Crusius et al.,
1998; Zhang et al., 2002). E5 also binds the 16-kDa subunit
C of vacuolar proton-ATPase (Conrad et al., 1993) and
decreases its ability to acidify endocytic compartments
(Straight et al., 1995; Thomsen et al., 2000). We have
measured the endosomal pH in HPV16 E5-expressing
HFKs and control cells after EGF starvation and subsequent
EGF (100 ng/ml) stimulation using a pH-sensitive endocytic
probe visualized by confocal microscopy. Consistent with
prior publications using pH-sensitive endocytic probes
(Straight et al., 1995; Thomsen et al., 2000), we observed
that the average pH of late endosomes in E5-expressing
cells was increased compared with control cells (data not
shown).
Our novel ELISA results show that there is a decrease in
MHC class II surface expression in E5-expressing cells
(Fig. 1, Table 1). Western blot analysis shows that, in
E5-expressing cells, the invariant chain proteolysis is par-
tially blocked (Fig. 2), as is the formation of mature peptide-
loaded SDS-stable MHC class II molecules (Fig. 3). Based
on the current knowledge of maturation of MHC class II
molecules and E5 function, we propose a model indicating
Fig. 3. HPV16 E5 blocks the formation of mature SDS-stable class II  dimers. LXSN- and L(16E5)SN-infected F551 HFKs were starved for EGF and
treated with 100 U/ml interferon- for 24 h and then stimulated with 100 ng/ml EGF and 500 U/ml interferon- for 5 and 24 h. Leupeptin was added at 0.5
mM to the LXSN-infected cells as a positive control. The cells were lysed at the indicated time and cell lysates were incubated with an equal volume of 2
SDS sample buffer without -mercaptoethanol for 2 h at room temperature and not boiled. An aliquot from each of the same cell lysates was boiled in an
equal volume of 2 SDS sample buffer in the presence of -mercaptoethanol. The treated lysates were analyzed by Western blot with monoclonal antibody
DA6.147 and XD5.A11 recognizing the  and  subunit of MHC class II dimer, respectively. The results shown are representative of three independent
infections of F551.
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the point at which HPV16 E5 might affect the maturation
and surface expression of MHC class II proteins (Fig. 4).
According to this model, E5 may affect the maturation of
MHC class II  indirectly by inhibiting the acidification of
late endosomes where the Ii is digested by a series of
proteases (Chapman, 1998), some of which function only in
an acidic environment (Blum et al., 1991). Alternatively, it
is possible that E5 inhibits protease activity. During the
course of these experiments, Thomsen et al. (2000) using a
membrane-permeable acidotrophic probe, reported that
HPV 16 E5 inhibited endocytic trafficking in monkey cells.
The acidic structures that were seen were smaller and dis-
persed in the cytoplasm compared to perinuclear staining in
control cells (Thomsen et al., 2000). Here, the detection of
invariant chain intermediates in E5-expressing human ker-
atinocytes strongly suggests that this chaperone for MHC
class II molecules is sorting to the right (endocytic) com-
partments for processing. Thus, the E5-mediated defect in
MHC class II protein surface expression and invariant chain
processing does not appear to be due to a disruption in
trafficking from the endoplasmic reticulum to endocytic
compartments.
Interestingly, cells from two individuals showed no sig-
nificant decrease of MHC class II cell-surface expression.
The reason for this lack of responsiveness to E5 remains
unclear. It is not due to a lack of E5 expression, based on
Northern analysis. Densitometric analysis indicated that all
transduced populations expressed E5 within approximately
twofold of the average. While the level of E5 in one of the
nonresponders (F562) was low, the level of expression in
the other nonresponder (F558) was at the average (data not
shown). The lack of response in cells from two foreskins
also does not seem to be due to foreskin-specific differences
in the effect of E5 on interferon-induced keratinocyte dif-
ferentiation. By Western analysis, both responders and non-
responders showed increased levels of involucrin expres-
sion in response to interferon-, as did the LXSN-infected
control cells (data not shown). We presume that the lack of
a decrease in MHC class II surface expression in two indi-
viduals is due to heterogeneity at the MHC class II DR
locus. For example, the rate of CLIP dissociation from DR
 complexes is allele-dependent (Avva and Cresswell,
1994; Patil et al., 2001). Thus, if the association of Ii with
MHC class II  chain were less stable, blockage of its
sequential degradation by E5 might be of lesser signifi-
cance. It is possible that such individuals would be at de-
creased risk for HPV-mediated disease. Consistent with this,
we have found that the HLA types detected in those foreskins
exhibiting decreased MHC class II, in contrast to those not
showing a decrease, have been reported to be associated with
cervical cancer (data not shown and Krul et al., 1999).
HPV16 plays an important role in the development of
premalignant cervical squamous intraepithelial lesions
(SIL) and cervical cancer (zur Hausen, 1991). The human
immune system can recognize HPV antigen and initiate a
subsequent immune response to infected cells (Stanley et
al., 1994; Tindle, 2002). Such host immune responses are
intimately related to the outcome of an HPV infection (Stan-
ley et al., 1994; Tyring, 2000). Individuals with depressed
cellular or humoral immunity are therefore at greater risk
for HPV-associated diseases (Ostrow et al., 1987; Vardy et
al., 1990; Jenson et al., 1991; Palefsky et al., 1999; Beskow
et al., 2001). HPVs have many mechanisms to thwart the
immune response (Tindle, 2002). HPV16 E6 and E7 can
down-modulate the host immune response by inhibiting
IL-18-induced interferon- production in HPV lesions (Lee
et al., 2001). HPV16 E7 can also mediate immune escape by
suppressing NF-kappaB activity (Spitkovsky et al., 2002).
In addition, HPV regulation of surface MHC class I expres-
sion may be important in the overall cellular immune re-
sponse to this pathogen (McFadden and Kane, 1994; Born-
stein et al., 1997). MHC class I is normally down-regulated
in HPV-related preinvasive neoplasia and cervical carci-
noma (Connor and Stern, 1990; Glew et al., 1993; Koopman
et al., 1998; Brady et al., 2000; Ritz et al., 2001). Specifi-
cally, HPV E7 can down-regulate transporter associated
with antigen presentation (TAP-1) and MHC class I expression
(Vambutas et al., 2000, 2001; Georgopoulos et al., 2000).
Our finding that HPV16 E5 can inhibit the maturation of
MHC class II and presumably decrease the ability of the
host to recognize infected cells suggests that E5 may, by
cooperating with other HPV oncoproteins, down-regulate
the host immune response, thereby contributing to viral
pathogenesis or carcinogenesis. By decreasing the surface
expression of MHC class II, the ability of CD4 T cells to
recognize the infected cells as foreign would be compro-
mised. CD4 cells would consequently neither function as
helper cells nor as cytotoxic T cells (Appay et al., 2002).
Materials and methods
Antibody
L243 is a mouse monoclonal antibody which recognizes
the HLA-DR  dimer (Maric et al., 1994). DA6.147 and
Fig. 4. The proposed model for the mechanism by which HPV16 E5 affects
MHC class II maturation in HFKs. The model is described in the text.
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XD5.A11 (Radka et al., 1984; Maric et al., 1994) are mono-
clonal antibodies which recognize the HLA-DR  and 
subunits, respectively. PIN1.1 is a monoclonal antibody
which binds the amino-terminal domain of human invariant
chain (Maric et al., 1994). NN4 is a mouse monoclonal anti-
body specific for human glycophorin purchased from ATCC.
The antibody to GAPDH was purchased from Chemikon.
Cell culture and retrovirus infection
Human foreskin keratinocytes (HFKs) were isolated
from neonates as previously described (Rheinwald and
Green, 1975; Zhang et al., 2002). HFKs were grown in
serum-free medium (K-SFM, GIBCO/BRL) supplemented
with human recombinant EGF (GIBCO/BRL) and bovine
pituitary extract (BPE, GIBCO/BRL), referred to as com-
plete K-SFM. PA317 cell lines, producing either a parental
retrovirus LXSN or a recombinant virus encoding HPV16
E5 [L(16E5)SN], were kindly provided by Denise Galloway
and were grown in DMEM with 10% fetal bovine serum.
Retrovirus infection was performed using either LXSN or
L(16E5)SN retrovirus (1  106 virus particles/ml) as pre-
viously described (Zhang et al., 2002).
ELISA assay
Keratinocytes were infected with either LXSN or
L(16E5)SN. After selection with G418, the cells were
plated in 96-well plates (1  104 cells/well) and grown in
complete K-SFM for 2 days at 37°C, 5% CO2. The cells
were washed with warm PBS and incubated with K-SFM
devoid of EGF but containing BPE and 100 U/ml interfer-
on- (Pero Tech, Inc.). After 24 h, the cells were changed to
K-SFM containing BPE, 100 ng/ml of EGF, and 500 U/ml
of interferon- for 5 or 24 h. Parallel wells of cells were
kept in complete K-SFM as untreated control cells. After
being fixed with 1% paraformaldehyde for 30 min at 4°C,
the cells were washed three times with ELISA wash buffer
(HBSS, 1% FBS) and subsequently incubated with anti-
class II antibodies, L243, or an isotype-matched irrelevant
antibody, NN4, as a specificity control at 4°C for 1 h. After
three washes, the cells were incubated with goat anti-mouse
monoclonal antibody conjugated with alkaline phosphatase
at 4°C for 1 h. The cells were then washed three times and
incubated with fresh substrate containing p-Nitrophenyl
phosphate (p-NPP Tablet, 5 mg/tablet, Sigma, N9389). The
surface MHC class II expression was monitored by OD405.
Triplicate samples were analyzed by comparing OD405 of
either LXSN- or L(16E5)SN-infected cells probed with
L243. Binding of NN4 to cells was subtracted from results
with the anti-MHC class II reagent L243.
Western blotting
Keratinocytes infected with either LXSN or L(16E5)SN
were grown in 10-cm dishes and treated with interferon- as
described in the ELISA assay. A parallel dish of LXSN-
infected cells also had 0.5 mM leupeptin (Riese et al., 1996)
added from the time of EGF starvation, as a positive control.
Cell lysates were made using cell lysis buffer with protease
inhibitors [50 mM Tris (pH 7.9), 150 mM NaCl, 1% Triton,
1 mM EDTA, 1 mM PMSF, 2 g/ml Leupeptin]. Protein
was quantitated with the Bio-Rad protein assay. The lysates
(about 40 g) were diluted with an equal volume of 2
SDS sample buffer and the proteins were separated by
SDS–PAGE and transferred to nitrocellulose. After block-
ing with 4% nonfat milk in TBST, the nitrocellulose mem-
brane was incubated with primary antibody for 2 h at 4°C.
The membrane was then washed three times with TBST and
incubated with secondary antibody conjugated with horse-
radish peroxidase (HRP) in TBST. After washing with
TBST five times, the membrane was developed with ECL
(Amersham Pharmacia).
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